Bafna Pharmaceuticals will present their approved FY26 financial results on May 29, 2026. Investors should note that the trading window is currently closed from April 1 to May 31, 2026, for designated persons and their relatives.

Bafna Pharma's valuation has been revised from high to fair, making it more appealing for potential investors. However, a closer look at the price is recommended due to Mojo Grade downgrading its rating from Strong Sell to Sell.

On April 13th, Bafna Pharmaceuticals experienced a significant drop of 5%, closing at Rs 133.87 due to an excessive selling pressure and lack of buying interest, leading to a supply-demand imbalance.

Bafna Pharma experienced a significant drop today, closing at Rs 108.42 - a decline of nearly 5%. The trading session was marked by intense selling pressure and minimal buying interest, indicating an unfavorable supply-demand ratio.